AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24257721 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for energy requirement assessment over 28 days
Number of subjects: 217
Study 24257721 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for energy requirement assessment
Number of subjects: 217
Study 23138590 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized temporary bi-ventricular (BiV) pacing
Number of subjects: 38
Study 23138590 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual-chamber right ventricular (RV) pacing
Number of subjects: 38
Study 20187283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean subjects
Number of subjects: 14
Study 20187283 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 14
Study 20187283 — intervention group
Group type: COMPARATOR
Intervention: Comparison between lean and obese subjects
Number of subjects: 14
Study 17360232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 7329
Study 17360232 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7329
Study 16244280 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Subtraction Angiography (DSA)
Number of subjects: 145
Study 16244280 — intervention group
Group type: COMPARATOR
Intervention: Multi-detector row CT angiography
Number of subjects: 145
Study 12087450 — intervention group
Group type: EXPERIMENTAL
Intervention: de Gramont
Number of subjects: 6
Study 12087450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokich
Number of subjects: 6
Study 12087450 — intervention group
Group type: EXPERIMENTAL
Intervention: raltitrexed
Number of subjects: 6
Study 9528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin (100 mg tablet)
Number of subjects: 625
Study 9528716 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg capsules, 2 capsules)
Number of subjects: 625
Study 9528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin
Number of subjects: 625
Study 9528716 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 625
Study 7543060 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 g/kg/day subcutaneously and daily)
Number of subjects: 32
Study 7543060 — intervention group
Group type: COMPARATOR
Intervention: Control (no G‐CSF)
Number of subjects: 32
Study 7543060 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 32
Study 7543060 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 2702989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (2 x 125 mg, 3 x 125 mg, or 2 x 250 mg daily)
Number of subjects: 101
Study 773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 65
Study 773500 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 65
Study 773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 65
Study 30966869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient enhanced multidisciplinary care (EMC)
Number of subjects: 80
Study 30966869 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (MR)
Number of subjects: 80
Study 29356210 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care interventions for MSK pain conditions
Number of subjects: 2483
Study 29356210 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain due to osteoarthritis (OA)
Number of subjects: 2483
Study 29356210 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, manual work, longer pain duration, widespread pain, anxiety/depression scores
Number of subjects: 2483
Study 27332770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single induction chemotherapy regimen C (four cycles of vincristine, carboplatin, and temozolomide) followed by marrow-ablative chemotherapy and autologous hematopoietic cell rescue.
Number of subjects: 32
Study 25169040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge
Number of subjects: 1400
Study 25169040 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration at the same time points
Number of subjects: 1400
Study 22076019 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks
Number of subjects: 34
Study 22076019 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study 21118874 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 134
Study 21118874 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 17391565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVOO) with 1125 mg polyphenols/kg and 350 mg tocopherols/kg
Number of subjects: 28
Study 17391565 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (ROO) with no polyphenols or tocopherols
Number of subjects: 28
Study 15887255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ELF magnetic field exposure (15 min)
Number of subjects: 20
Study 15887255 — intervention group
Group type: COMPARATOR
Intervention: Sham session (15 min)
Number of subjects: 20
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I (clomiphene citrate and gonadotrophins)
Number of subjects: 46
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol II (gonadotrophins started during clomiphene citrate administration)
Number of subjects: 46
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with premature LH surge in Protocol I
Number of subjects: 46
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without premature LH surge in Protocol I
Number of subjects: 46
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with premature LH surge in Protocol II
Number of subjects: 46
Study 12831586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without premature LH surge in Protocol II
Number of subjects: 46
Study 10511135 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 45
Study 10511135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 45
Study 8561057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (15% carbohydrate)
Number of subjects: 43
Study 8561057 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (45% carbohydrate)
Number of subjects: 43
Study 1841833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bovine surfactant (100 mg/kg birth weight)
Number of subjects: 164
Study 1841833 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bovine surfactant (50 mg/kg birth weight)
Number of subjects: 164
Study 6288396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 2 mg/kg
Number of subjects: 0
Study 6288396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 2 + 4 mg/kg
Number of subjects: 0
Study 6288396 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 9.2 +/- 0.9 mg/kg
Number of subjects: 0
Study 30298417 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration oxygen group
Number of subjects: 94
Study 30298417 — intervention group
Group type: COMPARATOR
Intervention: Standard concentration oxygen group
Number of subjects: 94
Study 29265379 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d for 5 days)
Number of subjects: 77
Study 29265379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched for 5 days)
Number of subjects: 77
Study 26782677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training programme and implementation of a 16-week pressure ulcer prevention protocol
Number of subjects: 1088
Study 26782677 — intervention group
Group type: COMPARATOR
Intervention: Usual pressure ulcer prevention care
Number of subjects: 1088
Study 24844460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based instruction (SIM)
Number of subjects: 32
Study 24844460 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based instruction (LEC)
Number of subjects: 32
Study 24844460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SIM and LEC)
Number of subjects: 32
Study 22538278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cyclodextrin complex (RA/CyD)
Number of subjects: 12
Study 22538278 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin (RA)
Number of subjects: 12
Study 21149720 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion perception
Number of subjects: 0
Study 21149720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperception
Number of subjects: 0
Study 17547484 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants instructed to engage in self-presentation during interactions with romantic partners
Number of subjects: 0
Study 17547484 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants interacting with opposite sex strangers
Number of subjects: 0
Study 17547484 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants evaluated by another person
Number of subjects: 0
Study 15786486 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (average dosage 12.3 mg/day)
Number of subjects: 10
Study 11882225 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1
Number of subjects: 120
Study 11882225 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.9 mg.kg‐1
Number of subjects: 120
Study 11882225 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 1.5 mg.kg‐1
Number of subjects: 120
Study 9018658 — intervention group
Group type: EXPERIMENTAL
Intervention: Root block
Number of subjects: 42
Study 9018658 — intervention group
Group type: COMPARATOR
Intervention: Subpubic block
Number of subjects: 42
Study 7910207 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 inactivated Immunogen
Number of subjects: 103
Study 3069238 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Pharmalgen, D. pteronyssinus)
Number of subjects: 38
Study 3069238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (histamine)
Number of subjects: 38
Study 30878157 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dextrose/0.2% lidocaine
Number of subjects: 42
Study 30878157 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.2% lidocaine)
Number of subjects: 42
Study 28929359 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular subtyping (BluePrint and MammaPrint)
Number of subjects: 5806
Study 28929359 — intervention group
Group type: COMPARATOR
Intervention: Surrogate pathological subtyping (PS)
Number of subjects: 5806
Study 26769021 — intervention group
Group type: EXPERIMENTAL
Intervention: Skype-guided self-help intervention
Number of subjects: 192
Study 26769021 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help intervention
Number of subjects: 192
Study 26769021 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 192
Study 24674384 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate combined with calcitonin
Number of subjects: 64
Study 24674384 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate
Number of subjects: 64
Study 22719796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy surveillance using a web‐based surveillance tool to monitor drug prescribing and kidney function trends.
Number of subjects: 396
Study 22719796 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacy services and CDS alerting (Control group).
Number of subjects: 396
Study 18417517 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Ultrasound (QUS) measurements at the calcaneus
Number of subjects: 432
Study 18417517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements at the lumbar spine
Number of subjects: 432
Study 18417517 — intervention group
Group type: EXPERIMENTAL
Intervention: QUS measurements at the calcaneus
Number of subjects: 432
Study 18417517 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA measurements
Number of subjects: 432
Study 17984410 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 32)
Number of subjects: 86
Study 16027572 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg via nebulization
Number of subjects: 70
Study 16027572 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg via nebulization
Number of subjects: 70
Study 12002290 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation laparoscopic cholecystectomy
Number of subjects: 50
Study 12002290 — intervention group
Group type: COMPARATOR
Intervention: Gasless abdominal wall lift laparoscopic cholecystectomy
Number of subjects: 50
Study 12002290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bridging external fixation
Number of subjects: 60
Study 9699834 — intervention group
Group type: COMPARATOR
Intervention: Bridging external fixation
Number of subjects: 60
Study 8042234 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-drug therapy (DT)
Number of subjects: 0
Study 8042234 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy (TT)
Number of subjects: 0
Study 8042234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver graft recipients
Number of subjects: 0
Study 8042234 — intervention group
Group type: EXPERIMENTAL
Intervention: Living-related graft recipients
Number of subjects: 0
Study 8042234 — intervention group
Group type: EXPERIMENTAL
Intervention: Early graft function recovery
Number of subjects: 0
Study 2969564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lung reexpansion through a fiberoptic bronchoscope using a large volume syringe
Number of subjects: 30
Study 2969564 — intervention group
Group type: COMPARATOR
Intervention: Conventional fiberoptic bronchoscopy suction
Number of subjects: 30
Study 7754792 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF plus MLT
Number of subjects: 14
Study 7754792 — intervention group
Group type: COMPARATOR
Intervention: TNF
Number of subjects: 14
Study 430774 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement by interpersonal similarity at the time of the emergency visit
Number of subjects: 0
Study 430774 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive written appeals
Number of subjects: 0
Study 430774 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone reinforcement
Number of subjects: 0
Study 30795780 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI resistance surveillance
Number of subjects: 46
Study 30795780 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI resistance surveillance including additional polymorphisms
Number of subjects: 46
Study 27862577 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted Gadobenate dimeglumine (GD) 0.1 mmol/kg
Number of subjects: 12
Study 27862577 — intervention group
Group type: COMPARATOR
Intervention: Diluted Gadobenate dimeglumine (GD) 0.1 mmol/kg
Number of subjects: 12
Study 27862577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (FE) 4 mg/kg
Number of subjects: 12
Study 27862577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (FE) 2 mg/kg
Number of subjects: 12
Study 25471273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) ingestion (500 mg kg(‐1) body mass)
Number of subjects: 16
Study 25471273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC; wheat flour)
Number of subjects: 16
Study 23408532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein Diet (HPD)
Number of subjects: 88
Study 23408532 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HCD)
Number of subjects: 88
Study 21403177 — intervention group
Group type: COMPARATOR
Intervention: report (received feedback reports)
Number of subjects: 265
Study 21403177 — intervention group
Group type: EXPERIMENTAL
Intervention: session (group sessions)
Number of subjects: 265
Study 21403177 — intervention group
Group type: EXPERIMENTAL
Intervention: face-to-face (personal interviews)
Number of subjects: 265
Study 21403177 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 265
Study 19562475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 19
Study 19562475 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 19
Study 17136040 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha (s1)‐casein hydrolysate (150 mg/day for 30 days)
Number of subjects: 63
Study 17136040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16133549 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/day
Number of subjects: 12
Study 16133549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 11133704 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCE with an ACIOL
Number of subjects: 2000
Study 11133704 — intervention group
Group type: COMPARATOR
Intervention: ICCE with aphakic spectacles (+11 dioptres)
Number of subjects: 2000
Study 9270561 — intervention group
Group type: EXPERIMENTAL
Intervention: cM-T412 antibody infusion
Number of subjects: 71
Study 8176056 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in delay between leading and lagging bursts (experiment 1)
Number of subjects: 0
Study 8176056 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in frequency (experiment 2)
Number of subjects: 0
Study 8176056 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in intensity (experiment 3)
Number of subjects: 0
Study 2885117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg daily combined with beta-adrenergic-blocking drugs
Number of subjects: 0
Study 2885117 — intervention group
Group type: COMPARATOR
Intervention: Beta-adrenergic-blocking drugs alone (single therapy)
Number of subjects: 0
Study 30803433 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP portal access
Number of subjects: 1500
Study 30803433 — intervention group
Group type: COMPARATOR
Intervention: Routine consultation
Number of subjects: 1500
Study 28486637 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood regeneration activities in 35 intervention areas (n = 4,197 subjects)
Number of subjects: 10892
Study 28486637 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of residence in regeneration neighborhoods
Number of subjects: 10892
Study 28486637 — intervention group
Group type: COMPARATOR
Intervention: Control areas (n = 6,695 subjects)
Number of subjects: 10892
Study 25342644 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child intervention
Number of subjects: 194
Study 25342644 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-only intervention
Number of subjects: 194
Study 25342644 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 194
Study 23426676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-band activity (18-30 Hz) in parietal regions
Number of subjects: 0
Study 23426676 — intervention group
Group type: EXPERIMENTAL
Intervention: High gamma band (>60 Hz) activity
Number of subjects: 0
Study 23426676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low gamma (<60 Hz) and alpha (∼10 Hz) bands
Number of subjects: 0
Study 21962943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter
Number of subjects: 122
Study 21962943 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (OM) only
Number of subjects: 122
Study 21962943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter (excluding cases with premature rupture of membranes)
Number of subjects: 122
Study 21962943 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (OM) only (excluding cases with premature rupture of membranes)
Number of subjects: 122
Study 19223890 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (group A)
Number of subjects: 324
Study 19223890 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (group B)
Number of subjects: 324
Study 17209328 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count
Number of subjects: 25
Study 17209328 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 cell count
Number of subjects: 25
Study 17209328 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 cell count
Number of subjects: 25
Study 17209328 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56 cell count
Number of subjects: 25
Study 17209328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte subset counts
Number of subjects: 25
Study 12626756 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended image with changes in any of the three central bars
Number of subjects: 11
Study 12626756 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended image with changes only in the middle bar
Number of subjects: 11
Study 10614032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg intravenous naloxone administered 2 minutes prior to ECT treatments
Number of subjects: 9
Study 10614032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 9
Study 8967882 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis (1 day before and 5 days after PTCA)
Number of subjects: 36
Study 8967882 — intervention group
Group type: COMPARATOR
Intervention: Control group (PTCA without LDL apheresis)
Number of subjects: 36
Study 1836766 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 1836766 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12
Study 1836766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 12
Study 1836766 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 6764321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganda 3.0/0.5
Number of subjects: 48
Study 6764321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganda 1.0/0.2
Number of subjects: 48
Study 30204301 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic glycan labeling (Sia5Ac and GalNAc/GlcNAc)
Number of subjects: 0